Immunex Corporation

Other

David L Urdal

Carl J March

Steven K Dower

John Ernest Sims

Virginia L Price

Michael C Deeley

Douglas Pat Cerretti

Diane Y Mochizuki

Alf D Larsen

Paul J Conlon, Iii

Helmut M Sassenfeld

Cosman

The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.

Antibodies to interleukin-1 receptors

Methods of using shuIL-1Rs to suppress IL-1 mediated immune responses in a mammal.

Method of using soluble human interleukin-1 receptors to suppress immune

Methods of using shulL-1Rs to suppress IL-1 mediated inflammation in a mammal.

Method of using soluble human interleukin-1 receptors to suppress

An analog human colony stimulating factor (hCSF) is disclosed, comprising a mutant amino acid sequence which is substantially homologous to the native sequence of an hCSF having at least one N-glycosylation site, wherein the mutant sequence comprises at least one amino acid substitution, deletion or insertion inactivating the N-glycosylation site.

DNA sequence encoding nonglycosylated analogs of human colony

Substantially purified and homogeneous soluble human interleukin-1 receptor (shuIL-1R) proteins, DNA encoding the shuIL-1R proteins and pharmaceutical compositions containing the shuIL-1R proteins are described.

Soluble interleukin-1 receptors

Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromatography in conjunction with a monoclonal antibody directed to the receptor. The purification process also includes reversed phased high performance liquid chromatography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has made possible the sequencing of the amino acid residues at the N-terminal of this protein molecule. Double-stranded cDNA is prepared from polyadenylated RNA extracted from cell lines or other sources known to produce IL-2 receptor. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools. Plasmid DNA prepared from these pools is hybridized with a labeled synthetic oligonucleotide probe corresponding to a portion of the amino acid sequence of the purified IL-2 receptor. The cDNA clone isolated with the probe is characterized by restriction enzyme mapping and sequenced by chain-termination method. The particular DNA clone that actually contains the gene coding for the functional IL-2 receptor is identified by expressing the clones in COS-7 monkey kidney cells and assaying for the expressed IL-2 receptor by its ability to bind IL-2 or a monoclonal antibody directed against the IL-2 receptor.

Purification of the IL-2 receptor

Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.

Process for purifying interleukin-1 receptors

Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.

Soluble human interleukin-1 receptors, compositions and method of use

The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro.sup.8 Asp.sup.15 Asp.sup.70) analog proteins expressed by transformed yeast of the species Saccharomyces cerevisiae, which when administered to a primate do not result in detectable urticaria.

Nonglycosylated human interleukin-3 analog proteins

Interleukin-1 receptors

Nonglycosylated analogs of human colony stimulating factors

A monoclonal antibody which specifically binds to the human IL-2 receptor, and a hybridoma which produces the antibody, are disclosed.

Hybridoma antibody which binds IL-2 receptor

Colony stimulating factor derived from malignant cells has been purified by use of various techniques including multiple high performance liquid chromotography steps. By this technique, colony stimulating factor has been resolved into distinct species, and one of the species denominated as CSF-2A, has been purified to homogeneity. The high purification of the CSF-2A has enabled the amino acid composition of this protein molecule to be partially sequenced with an automated sequencer.

Process for producing homogeneous colony stimulating factor

Interleukin-2 receptor derived from normal and malignant cells has been purified by use of various techniques including affinity chromotography in conjunction with a monoclonal antibody directed to the receptor. Purification also involved reversed phased high performance liquid chromotography. By these techniques, interleukin-2 receptor has been purified to homogeneity. The high purification of the interleukin-2 receptor has enabled this protein molecule to be partially sequenced.

Growing community of inventors

Seattle, WA, United States of America

David L Urdal